Axitinib Accord (axitinib)
Generic
- Region
- 🇪🇺 EU
- Active substance
- axitinib
- Company
- Accord Healthcare S.L.U.
- Status
- Authorised
- Therapeutic area
- Carcinoma, Renal Cell
- CHMP opinion
- Thu 25 Jul 2024
- EU approval
- Thu 19 Sep 2024
- Designations
- Generic
- Application
- EMEA/H/C/006206
- ATC
- L01EK01
- Official record
- www.ema.europa.eu
Indication
Axitinib Accord is indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of prior treatment with sunitinib or a cytokine.
Regulatory milestones
No milestones recorded in the last year.
Same substance in other markets
- 🇪🇺 Inlyta Authorised · Pfizer Europe MA EEIG
Follow Axitinib Accord
Get VigiEye Daily: approvals, opinions, safety actions and PDUFA dates every morning.
Information from official EMA, FDA, Federal Register and SEC records. Dates marked company-announced come from the company's own SEC filing; dates marked estimate are calculated, not official. Not investment or medical advice; always confirm on the source.